Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study
- PMID: 3406051
- DOI: 10.1055/s-2007-1014666
Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study
Abstract
Memantine was investigated in a phase II double-blind trial on 30 elderly patients by comparison with a placebo with the aid of several psychometric tests. It was found that vigilance, short-term memory, and concentration improve significantly under Memantine. It was also found that Memantine exerted a beneficial effect on psychiatric and neurological symptoms despite the presence of an organic psychosyndrome of many years' duration and multiple morbidity. The tolerance of the preparation was good in virtually all cases and a gradually increasing dosage is recommended. On the basis of these findings the authors assume that the therapeutic efficiency can be confirmed in a phase III trial.
Similar articles
-
Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.Arzneimittelforschung. 1992 Jul;42(7):904-13. Arzneimittelforschung. 1992. PMID: 1418054 Clinical Trial.
-
Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.Arzneimittelforschung. 1991 Aug;41(8):773-80. Arzneimittelforschung. 1991. PMID: 1781796 Clinical Trial.
-
Randomized controlled trial of memantine in dementia associated with Parkinson's disease.Mov Disord. 2009 Jun 15;24(8):1217-21. doi: 10.1002/mds.22495. Mov Disord. 2009. PMID: 19370737 Clinical Trial.
-
Drug therapy of dementia in elderly patients. A review.Nord J Psychiatry. 2005;59(2):71-7. doi: 10.1080/08039480510022936. Nord J Psychiatry. 2005. PMID: 16195103 Review.
-
Amantadine and memantine: a comprehensive review for acquired brain injury.Brain Inj. 2020 Feb 23;34(3):299-315. doi: 10.1080/02699052.2020.1723697. Epub 2020 Feb 20. Brain Inj. 2020. PMID: 32078407 Review.
Cited by
-
Memantine.Drugs Aging. 2003;20(6):465-76; discussion 477-8. doi: 10.2165/00002512-200320060-00005. Drugs Aging. 2003. PMID: 12710865 Review.
-
Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study.J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):259-64. doi: 10.1136/jnnp.61.3.259. J Neurol Neurosurg Psychiatry. 1996. PMID: 8795596 Free PMC article. Clinical Trial.
-
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Clin Pharmacokinet. 2017 Mar;56(3):251-261. doi: 10.1007/s40262-016-0449-5. Clin Pharmacokinet. 2017. PMID: 27665574 Review.
-
Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.Ther Clin Risk Manag. 2018 Sep 18;14:1737-1745. doi: 10.2147/TCRM.S139545. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30271159 Free PMC article. Review.
-
Glutamate: its role in learning, memory, and the aging brain.Psychopharmacology (Berl). 1993;111(4):391-401. doi: 10.1007/BF02253527. Psychopharmacology (Berl). 1993. PMID: 7870979 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical